ANNX
NASDAQ HealthcareAnnexon, Inc. - common stock
Biotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barrรฉ syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
๐ Market Data
| Price | $5.75 |
|---|---|
| Volume | 1,212,018 |
| Market Cap | 934.42M |
| Beta | 1.150 |
| RSI (14-Day) | 48.6 |
| 200-Day MA | $4.25 |
| 50-Day MA | $5.65 |
| 52-Week High | $7.18 |
| 52-Week Low | $1.60 |
| Forward P/E | -6.01 |
| Price / Book | 4.06 |
๐ฏ Investment Strategy Scores
ANNX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (71/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (21/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ANNX in your text
Paste any article, transcript, or post โ the tool will extract ANNX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.